Institution
Eastern Virginia Medical School
Education•Norfolk, Virginia, United States•
About: Eastern Virginia Medical School is a education organization based out in Norfolk, Virginia, United States. It is known for research contribution in the topics: Population & Pregnancy. The organization has 5437 authors who have published 9027 publications receiving 333935 citations. The organization is also known as: EVMS.
Topics: Population, Pregnancy, Prostate cancer, Sperm, Medicine
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer and immune responses to the immunizing antigen were observed in patients who received sipuleUcel- T.
Abstract: Background Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. Methods In this double-blind, placebo-controlled, multicenter phase 3 trial, we randomly assigned 512 patients in a 2:1 ratio to receive either sipuleucel-T (341 patients) or placebo (171 patients) administered intravenously every 2 weeks, for a total of three infusions. The primary end point was overall survival, analyzed by means of a stratified Cox regression model adjusted for baseline levels of serum prostate-specific antigen (PSA) and lactate dehydrogenase. Results In the sipuleucel-T group, there was a relative reduction of 22% in the risk of death as compared with the placebo group (hazard ratio, 0.78; 95% confidence interval [CI], 0.61 to 0.98; P = 0.03). This reduction represented a 4.1-month improvement in median survival (25.8 months in the sipuleucel-T group vs. 21.7 months in the placebo group). The 36-month survival probability was 31.7% in the sipuleucel-T group versus 23.0% in the placebo group. The treatment effect was also observed with the use of an unadjusted Cox model and a log-rank test (hazard ratio, 0.77; 95% CI, 0.61 to 0.97; P = 0.02) and after adjustment for use of docetaxel after the study therapy (hazard ratio, 0.78; 95% CI, 0.62 to 0.98; P = 0.03). The time to objective disease progression was similar in the two study groups. Immune responses to the immunizing antigen were observed in patients who received sipuleucel-T. Adverse events that were more frequently reported in the sipuleucel-T group than in the placebo group included chills, fever, and headache. Conclusions The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer. No effect on the time to disease progression was observed. (Funded by Dendreon; ClinicalTrials.gov number, NCT00065442.)
4,840 citations
••
University of Texas MD Anderson Cancer Center1, Oregon Health & Science University2, Mount Sinai St. Luke's and Mount Sinai Roosevelt3, American Cancer Society4, Veterans Health Administration5, Emory University6, Johns Hopkins University School of Medicine7, University of Pennsylvania8, Eastern Virginia Medical School9, Mayo Clinic10, Kaiser Permanente11, University of Wisconsin-Madison12, Indiana University – Purdue University Indianapolis13, Creighton University14, Memorial Sloan Kettering Cancer Center15
TL;DR: Clinicians should be prepared to offer patients a choice between a screening test that is effective at both early cancer detection and cancer prevention through the detection and removal of polyps and those that can detect cancer early and also can detect adenomatous polyps.
2,876 citations
••
Baylor College of Medicine1, Stanford University2, University of Pittsburgh3, University of California, Los Angeles4, Sapienza University of Rome5, Loyola University Chicago6, University of Texas at Austin7, University of Texas Southwestern Medical Center8, Boston Children's Hospital9, University of Chicago10, Johns Hopkins University School of Medicine11, Georgetown University12, University of Toronto13, Gannon University14, American Academy of Pediatrics15, University of Louisville16, University of Washington17, Eastern Virginia Medical School18
TL;DR: A scientifically rigorous update to the National Sleep Foundation's sleep duration recommendations, determined expert recommendations for sufficient sleep durations across the lifespan using the RAND/UCLA Appropriateness Method.
2,568 citations
••
TL;DR: The panel recommended that investigators be allowed to use the ASTRO Consensus Definition after EBRT alone (no hormonal therapy) with strict adherence to guidelines as to "adequate follow-up."
Abstract: In 1996 the American Society for Therapeutic Radiology and Oncology (ASTRO) sponsored a Consensus Conference to establish a definition of biochemical failure after external beam radiotherapy (EBRT). The ASTRO definition defined prostate specific antigen (PSA) failure as occurring after three consecutive PSA rises after a nadir with the date of failure as the point halfway between the nadir date and the first rise or any rise great enough to provoke initiation of therapy. This definition was not linked to clinical progression or survival; it performed poorly in patients undergoing hormonal therapy (HT), and backdating biased the Kaplan-Meier estimates of event-free survival. A second Consensus Conference was sponsored by ASTRO and the Radiation Therapy Oncology Group in Phoenix, Arizona, on January 21, 2005, to revise the ASTRO definition. The panel recommended: (1) a rise by 2 ng/mL or more above the nadir PSA be considered the standard definition for biochemical failure after EBRT with or without HT; (2) the date of failure be determined "at call" (not backdated). They recommended that investigators be allowed to use the ASTRO Consensus Definition after EBRT alone (no hormonal therapy) with strict adherence to guidelines as to "adequate follow-up." To avoid the artifacts resulting from short follow-up, the reported date of control should be listed as 2 years short of the median follow-up. For example, if the median follow-up is 5 years, control rates at 3 years should be cited. Retaining a strict version of the ASTRO definition would allow comparisons with a large existing body of literature.
2,331 citations
••
Memorial Sloan Kettering Cancer Center1, Harvard University2, Indiana University3, University of Minnesota4, University of Utah5, Boston University6, University of California, San Diego7, Kaiser Permanente8, Virginia Commonwealth University9, Eastern Virginia Medical School10, University of Texas Southwestern Medical Center11, Mayo Clinic12
TL;DR: These guidelines differ from those published in 1997 in several ways: the screening interval for double contrast barium enema has been shortened to 5 years, and colonoscopy is the preferred test for the diagnostic investigation of patients with findings on screening and for screening patients with a family history of hereditary nonpolyposis colorectal cancer.
2,196 citations
Authors
Showing all 5473 results
Name | H-index | Papers | Citations |
---|---|---|---|
Russel J. Reiter | 169 | 1646 | 121010 |
David W. Johnson | 160 | 2714 | 140778 |
Ted M. Dawson | 155 | 537 | 94434 |
Steven J. Jacobsen | 123 | 662 | 62716 |
Simin Liu | 118 | 485 | 73940 |
Roger I. Glass | 116 | 474 | 49151 |
Howard I. Maibach | 116 | 1821 | 60765 |
Robert A. Rosenheck | 114 | 963 | 54357 |
Herbert W. Virgin | 112 | 317 | 47138 |
Yutaka Yasui | 101 | 472 | 38776 |
Chawnshang Chang | 97 | 534 | 35629 |
Michael D. Ward | 95 | 823 | 36892 |
Hans Lilja | 93 | 493 | 37236 |
Paul E. Marik | 89 | 621 | 32719 |
Zev Rosenwaks | 89 | 772 | 32039 |